Myriad, Sanofi to team on diabetes biomarker Dx discovery work

A Myriad Genetics ($MYGN) subsidiary will team up with Sanofi ($SNY) and others to conduct protein biomarker discovery work on more than 8,000 serum samples from prediabetes or Type 2 diabetes patients. The goal of the project: Identify biomarkers that could help improve patient care and treatment. Myriad said the deal could generate up to $10 million in companion diagnostic service revenue over the next two fiscal years. Myriad may need the extra revenue as it revs up for a U.S. Supreme Court fight over whether it has the right to own intellectual property for isolated genes involved in its cancer diagnostics. Release

Suggested Articles

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,